Empatica, a Boston, MA-based digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, announced the clearance of its Empatica Health Monitoring Platform by the U.S. Food and Drug Administration (FDA).
Empatica also announced that it closed its Series B funding round. The round was led by Sanofi Ventures and RA Capital Management, with participation from Black Opal Ventures.
The investment will enable Empatica to expand its suite of digital biomarkers, for use in patient care and as digital endpoints in clinical trials.
The Empatica Health Monitoring Platform is a full-stack remote health monitoring and data collection solution for research and healthcare professionals, built on data collected by Empatica's medical-grade, CE-certified EmbracePlus wearable.
In addition, the Platform includes Empatica's proprietary Care software suite, secure cloud infrastructure, and clinically validated digital biomarkers.
The platform is being used globally by major pharmaceutical companies to continuously gather and analyze physiological data for clinical trials evaluating the impact of novel therapeutics, with Empatica collaborating to develop digital biomarkers for use as endpoints.
Company: Empatica Inc
Raised: Undisclosed
Round: Series B
Funding Month: November 2022
Lead Investors: Sanofi Ventures and RA Capital Management
Additional Investors: Black Opal Ventures
Company Website: https://www.empatica.com/
Software Category: Health Monitoring Platform
About the Company: Empatica Inc is a pioneer in continuous, unobtrusive remote health monitoring driven by AI. Empatica's platform and technology are used by thousands of institutional partners for research purposes, in studies examining stress, sleep, epilepsy, migraine, depression, addiction, and other conditions. Its flagship medical wearable, EmbracePlus, has been developed with key partners including HHS, USAMRDC, and the NASA-funded TRISH. Empatica's Platform has been cleared for continuous data collection to monitor blood oxygen saturation (SpO2) during rest, peripheral skin temperature, activity associated with movement during sleep, and Electrodermal Activity (EDA).
Source: https://www.prnewswire.com/news-releases/empatica-receives-new-fda-clearance-for-its-health-monitoring-platform-and-announces-series-b-financing-301685336.html